mirtazapine has been researched along with Epilepsy in 3 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of the noradrenergic and specific serotonergic antidepressant mirtazapine on motor cortex excitability in epilepsy patients with depression and in healthy controls, using transcranial magnetic stimulation (TMS)." | 7.73 | Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. ( Gerschlager, W; Langosch, JM; Münchau, A; Orth, M; Rothwell, JC; Trimble, MR, 2005) |
| "To examine the effects of the noradrenergic and specific serotonergic antidepressant mirtazapine on motor cortex excitability in epilepsy patients with depression and in healthy controls, using transcranial magnetic stimulation (TMS)." | 3.73 | Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. ( Gerschlager, W; Langosch, JM; Münchau, A; Orth, M; Rothwell, JC; Trimble, MR, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Juckel, G | 2 |
| Schüle, C | 1 |
| Pogarell, O | 2 |
| Rupp, D | 1 |
| Laakmann, G | 1 |
| Hegerl, U | 2 |
| Münchau, A | 1 |
| Langosch, JM | 1 |
| Gerschlager, W | 1 |
| Rothwell, JC | 1 |
| Orth, M | 1 |
| Trimble, MR | 1 |
| Sterr, A | 1 |
| Padberg, F | 1 |
| Amann, B | 1 |
| Mergl, R | 1 |
| Mulert, C | 1 |
3 other studies available for mirtazapine and Epilepsy
| Article | Year |
|---|---|
Epileptiform EEG patterns induced by mirtazapine in both psychiatric patients and healthy volunteers.
Topics: Adult; Antidepressive Agents; Electroencephalography; Epilepsy; Female; Humans; Mental Disorders; Mi | 2003 |
Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression.
Topics: Adult; Antidepressive Agents, Tricyclic; Arousal; Depressive Disorder, Major; Electric Stimulation; | 2005 |
Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents; Cerebral Cortex; Citalopram; Cyclohexanols; Electroence | 2006 |